Cutaneous manifestations of nontargeted and targeted chemotherapies
- PMID: 27178698
- DOI: 10.1053/j.seminoncol.2016.02.018
Cutaneous manifestations of nontargeted and targeted chemotherapies
Abstract
Care of the oncologic patient requires an integral understanding of the adverse reactions of chemotherapy. With the advent of targeted agents and immunomodulating therapies, reactions to these newer treatments are of clinical interest. Cutaneous side effects of chemotherapeutic agents, including toxic erythema and mucositis, are common and may require cessation of treatment if associated with discomfort, superinfection, or negative impact on quality of life. This article reviews the cutaneous adverse reactions and treatment options of both conventional cytotoxic chemotherapeutic agents and newer targeted, multikinase inhibitors and immunomodulating therapies. An understanding of possible cutaneous reactions by all providers involved in the care of the oncologic patient is critical for prompt recognition, allowing for appropriate treatment and referral to dermatologists when necessary.
Keywords: Cutaneous adverse reactions; Cytotoxic chemotherapy; Immunotherapy; Multikinase inhibitors; Targeted chemotherapy; Toxic erythema.
Copyright © 2016. Published by Elsevier Inc.
Similar articles
-
Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane.J Am Acad Dermatol. 2015 Feb;72(2):203-18; quiz 219-20. doi: 10.1016/j.jaad.2014.07.032. J Am Acad Dermatol. 2015. PMID: 25592338 Review.
-
Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails.Am J Clin Dermatol. 2018 Nov;19(Suppl 1):31-39. doi: 10.1007/s40257-018-0384-3. Am J Clin Dermatol. 2018. PMID: 30374901 Free PMC article. Review.
-
Cutaneous adverse effects of targeted therapies: Part II: Inhibitors of intracellular molecular signaling pathways.J Am Acad Dermatol. 2015 Feb;72(2):221-36; quiz 237-8. doi: 10.1016/j.jaad.2014.07.033. J Am Acad Dermatol. 2015. PMID: 25592339 Review.
-
Cutaneous drug eruptions associated with the use of new oncological drugs.Chem Immunol Allergy. 2012;97:191-202. doi: 10.1159/000335632. Epub 2012 May 3. Chem Immunol Allergy. 2012. PMID: 22613863
-
Survival of melanoma patients treated with targeted therapy and immunotherapy after systematic upfront control of brain metastases by radiosurgery.Eur J Cancer. 2017 Oct;84:44-54. doi: 10.1016/j.ejca.2017.07.017. Epub 2017 Aug 4. Eur J Cancer. 2017. PMID: 28783540
Cited by
-
Cutaneous Toxicities of Molecular Targeted Therapies.Maedica (Bucur). 2017 Jan;12(1):48-54. Maedica (Bucur). 2017. PMID: 28878837 Free PMC article.
-
PI3K inhibitors protect against glucocorticoid-induced skin atrophy.EBioMedicine. 2019 Mar;41:526-537. doi: 10.1016/j.ebiom.2019.01.055. Epub 2019 Feb 5. EBioMedicine. 2019. PMID: 30737086 Free PMC article.
-
Penile-scrotal erythrodysesthesia among rectal cancer patients receiving fluoropyrimidine-based chemoradiation: a case report series.Int J Colorectal Dis. 2024 May 23;39(1):75. doi: 10.1007/s00384-024-04647-2. Int J Colorectal Dis. 2024. PMID: 38780794 Free PMC article.
-
Targeting of epigenetic regulators in neuroblastoma.Exp Mol Med. 2018 Apr 27;50(4):1-12. doi: 10.1038/s12276-018-0077-2. Exp Mol Med. 2018. PMID: 29700278 Free PMC article. Review.
-
Targeted Therapy for Advanced Thyroid Cancer: Kinase Inhibitors and Beyond.Endocr Rev. 2019 Dec 1;40(6):1573-1604. doi: 10.1210/er.2019-00007. Endocr Rev. 2019. PMID: 31322645 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous